Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Recce Pharmaceuticals’ (ASX:RCE) approval from the Indonesian Government for a phase 3 clinical trial of its topical gel for diabetic foot infections.

The risk of a person with diabetes developing a foot ulcer has been estimated to be as high as 34%  and about half of all diabetic foot ulcers develop infection which can even lead to death.

Tune in to get the latest.

 

While Recce Pharmaceuticals is a Stockhead advertiser, it did not sponsor this content.

Read MoreHealth

Featured Companies

You might be interested in